Events / Media releases

2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April.

https://www.eventscribe.net/2021/ASAM/SearchByExpoCompany.asp

Comments Off on 2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April.
13 . 4 . 2021
Media releases

2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients

Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients ALA-1000 is the first, three-month slow-release Buprenorphine injection. Initial results show a low initial burst without dose dumping effect, good safety, and tolerability. ALA-1000 has the potential to significantly increase compliance and reduce the risk of relapse in patients treated and stabilized with oral medications or other, shorter-interval Buprenorphine LAIs.…

Comments Off on 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients
10 . 3 . 2021
Media releases

2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000

Alar Pharmaceuticals Inc., a new drug development company focused on long-acting release drug products, has announced that it concluded its pre-Investigational New Drug (pre-IND) meeting with U.S. Food and Drug Administration (FDA) for ALA-3000 on August 21, 2020. ALA-3000 is a developing long-acting new drug to treat patients with treatment-resistant depression (TRD), which is designed with specific features to have safety benefits. In the written response, US FDA agrees with…

Comments Off on 2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000
24 . 8 . 2020